Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396801 | 1.00 | NPC1 (0.50) | NPC1RAB9APKMNAMPTSMN1; SMN2 | |
| Carbamic Acid SCHEMBL28798472 | 0.83 | NPC1 (0.53) | NPC1RAB9APKMNAMPTSMN1; SMN2 | |
| SCHEMBL1339748 | 0.81 | NAPRT (0.43) | NPC1RAB9ASMN1; SMN2LMNAHIF1A | |
| SCHEMBL296522 | 0.80 | MDM2 (0.44) | RAB9APRKCIALDH1A1KDM4ELMNA | |
| SCHEMBL15943547 | 0.76 | NPC1 (0.46) | NPC1RAB9APKMNAMPTSMN1; SMN2 | |
| SCHEMBL2733293 | 0.75 | RAB9A (0.47) | NPC1RAB9APKMNAMPTSMN1; SMN2 | |
| SCHEMBL8817823 | 0.75 | NAMPT (0.50) | NPC1RAB9APKMNAMPTSMN1; SMN2 | |
| SCHEMBL4855558 | 0.75 | ALDH1A1 (0.44) | NPC1RAB9APKMALDH1A1LMNA | |
| SCHEMBL7041466 | 0.72 | NAMPT (0.52) | NPC1RAB9APKMNAMPTSMN1; SMN2 | |
| SCHEMBL6979885 | 0.71 | CYP1A2 (0.54) | NPC1RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023378-B2 | Covalently linked antigen-antibody conjugates | HOFFMANN-LA ROCHE INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-4389772-A1 | TARGETED DELIVERY OF THERAPEUTIC ENZYMES | Joint-Stock Company "Generium" (RU) | 2024-06-26 | — | — | EP | disclosed |
| EP-3089996-B1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | HOFFMANN LA ROCHE (CH) | 2021-07-28 | — | — | EP | disclosed |
| US-20210069338-A1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | HOFFMANN-LA ROCHE INC. | 2021-03-11 | — | — | US | disclosed |
| EP-3138580-B1 | COVALENTLY LINKED ANTIGEN-ANTIBODY CONJUGATES | HOFFMANN LA ROCHE (CH) | 2021-03-03 | — | — | EP | disclosed |
| EP-3089758-B1 | COVALENTLY LINKED HELICAR-ANTI-HELICAR ANTIBODY CONJUGATES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10806795-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200164064-A1 | COVALENTLY LINKED ANTIGEN-ANTIBODY CONJUGATES | HOFFMANN-LA ROCHE INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10561737-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10407511-B2 | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-2661282-A1 | A PHARMACEUTICAL COMPOSITION OF A COMPLEX OF AN ANTI-DIG ANTIBODY AND DIGOXIGENIN THAT IS CONJUGATED TO A PEPTIDE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20130280279-A1 | PHARMACEUTICAL COMPOSITION OF A COMPLEX OF AN ANTI-DIG ANTIBODY AND DIGOXIGENIN THAT IS CONJUGATED TO A PEPTIDE | HOFFMANN LA ROCHE (US) | 2013-10-24 | — | — | US | disclosed |
| US-8268784-B2 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012093068-A1 | A PHARMACEUTICAL COMPOSITION OF A COMPLEX OF AN ANTI-DIG ANTIBODY AND DIGOXIGENIN THAT IS CONJUGATED TO A PEPTIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| EP-1962959-B1 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20100137223-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | CONDE-KNAPE KARIN | 2010-06-03 | — | — | US | disclosed |
| US-7642244-B2 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1962959-A2 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065808-A2 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135351-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | CONDE-KNAPE KARIN | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135351-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | NPY2R, NPY1R, NPY4R | NPC1 1952/4885RAB9A 2609/4885PKM 2676/4885 |
| US-20100137223-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | NPY2R, NPY1R, NPY5R | NPC1 3833/4885RAB9A 1819/4885PKM 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.